Welcome to our dedicated page for Aclaris Therapeutics SEC filings (Ticker: ACRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through Aclaris Therapeutics’ multi-trial disclosures, royalty agreements, and cash runway notes can exceed 250 pages per filing. Pinpointing when a kinase inhibitor enters Phase 2 or tracking executive option exercises shouldn’t require a doctorate in regulatory science.
Stock Titan’s AI-powered analysis decodes every Aclaris Therapeutics SEC filing in real time. Need the Aclaris Therapeutics quarterly earnings report 10-Q filing? Our platform highlights R&D spend, liquidity updates, and segment revenue in plain English. Wondering about Aclaris Therapeutics insider trading Form 4 transactions? Receive instant alerts the moment executives buy or sell shares. From the Aclaris Therapeutics annual report 10-K simplified to each Aclaris Therapeutics 8-K material events explained, our summaries surface trial milestones, licensing income, and risk factors in minutes rather than hours.
Investors use these insights to:
- Monitor Aclaris Therapeutics Form 4 insider transactions real-time before pivotal data releases
- Compare quarter-over-quarter R&D burn without wading through accounting footnotes
- Review Aclaris Therapeutics proxy statement executive compensation alongside dilution projections
- Assess cash needs via shelf registration S-3 filings
On 30 June 2025, Aclaris Therapeutics, Inc. (Nasdaq: ACRS) filed an 8-K solely to furnish an updated corporate overview presentation (Exhibit 99.1) under Item 7.01 – Regulation FD Disclosure. The deck has been posted to the company’s website and is not deemed “filed” for Exchange Act liability or for incorporation by reference. No financial results, strategic transactions, or operational updates were disclosed. All other sections, including Item 9.01, merely list the exhibit numbers, and the filing was signed by CFO Kevin Balthaser.
FAQ
What is the current stock price of Aclaris Therapeutics (ACRS)?
What is the market cap of Aclaris Therapeutics (ACRS)?
